Activating Immunity

Plexium is modulating E3 ligases to induce immunity

The immune system plays an important sentinel role

in protecting us from cellular insults.

The activity of the immune system can diminish with age and can be actively impaired by tumor cells or pro-inflammatory cells in the central nervous system during disease.

Plexium is utilizing the DELPhe platform to identify E3 ligase-binding small molecules that will redirect the immune system or increase its function in immunosuppressive environments. With an understanding of the relevant activating and inhibitory signals that impact immune cell function, Plexium identifies small molecules that will restore desired signaling and optimize beneficial immune cell responses.

Direct Solid Tumor Cell Killing

Plexium is harnessing E3 ligases to selectivity target high unmet medical need cancers including small cell lung and breast tumors

Solid tumor growth is complex and still not well understood.

Although treatment successes have been seen in certain types of solid tumors, several types of aggressive lung and breast cancer have not seen new therapies in over 30 years. These high unmet medical need tumors are a focus of drug discovery at Plexium.

Selective degradation of proteins associated with cancer or immune suppression is expected to deliver more effective cancer therapy. Plexium is utilizing the DELPhe platform to identify E3 ligase modulating small molecules or small molecules that direct a pathogenic protein to an E3 ligase in disease representative cells. Hit compounds from DELPhe screens will be advanced into lead optimization and downstream development to deliver a pipeline of monovalent degrader therapeutics.